These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30706396)

  • 1. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic herpes simplex virus engineering and preparation.
    Agarwalla PK; Aghi MK
    Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y; Saeki Y; Fukuhara H; Todo T
    Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
    Jeyaretna DS; Kuroda T
    Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
    Jahan N; Ghouse SM; Martuza RL; Rabkin SD
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of HSV-1 to an oncolytic virus.
    Nakashima H; Chiocca EA
    Methods Mol Biol; 2014; 1144():117-27. PubMed ID: 24671680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
    J Virol; 2017 May; 91(10):. PubMed ID: 28250120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
    Kuroda T; Martuza RL; Todo T; Rabkin SD
    BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer.
    Reale A; Krutzke L; Cadamuro M; Vitiello A; von Einem J; Kochanek S; Palù G; Parolin C; Calistri A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
    Hong B; Sahu U; Mullarkey MP; Kaur B
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering HSV-1 Vectors for Gene Therapy.
    Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
    Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.